Can a targeted antibody boost chemotherapy for a rare bile duct cancer?
Disease control
Not yet recruiting
This phase 2 trial is testing whether adding zolbetuximab, an antibody that targets a protein called claudin 18.2, to standard chemotherapy can help control advanced or metastatic biliary tract cancers. The study enrolls adults whose tumors overexpress this protein. Participants …
Phase: PHASE2 • Sponsor: Midhun Malla • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC